JPMA Reports Overseas Drug Makers Favoring China Over Japan As R&D Base
This article was originally published in PharmAsia News
Executive Summary
A Japan Pharmaceutical Manufacturers Association policy report shows that U.S. and European drug makers prefer China over Japan in establishing research and development bases. The reasons cited by the JPMA report include China's national policy to promote science and technology and its active recruitment of talent and enterprises from overseas. Additionally, China fosters clusters of domestic and foreign researchers and has improved the environment for R&D, such as the Shanghai Zhangjiang Hi-tech Park, where 120 venture companies, CROs and Shanghai Institute of Material Medica are based. The report also criticized Japan's late response to internationalization in R&D. (Click here for more - Japanese language